Loading...
Market
Will J&J's new prophylactic strategies further reduce infusion-related reactions by March 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Johnson & Johnson official press release or peer-reviewed publication
Story
J&J: Dexamethasone Reduces Infusion Reactions in Lung Cancer Patients by 22.5%
Sep 10, 2024, 09:19 PM
Johnson & Johnson ($JNJ) has announced that dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous Rybrevant (amivantamab-vmjw). The prophylaxis regimen with 8 mg dexamethasone taken for two days prior to the first infusion met the primary endpoint of incidence of infusion-related reactions at C1D1. Ongoing studies are evaluating additional prophylactic strategies to further reduce these reactions. The pre-medication regimen showed an infusion-related reaction rate of 22.5% with intravenous Rybrevant.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
